Q-omics provides the consensus-scored STRADBP1 profile across patient tissues and cancer cell-line models. STRADBP1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, STRADBP1 is differentially expressed in 8, with the highest sampling consensus in LUSC. Additionally, STRADBP1 RNA expression shows 8,929 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and LUSC as cancer lineages where STRADBP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for STRADBP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes STRADBP1 survival associations across molecular data types. STRADBP1 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible STRADBP1 RNA expression–survival associations across cancer types. High STRADBP1 expression shows unfavorable associations in ACC, KIRP, UVM, DLBC and UCEC, but favorable associations in BLCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for STRADBP1 RNA expression.
This table summarizes STRADBP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for STRADBP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. STRADBP1 shows lower tumor expression in LUSC, LUAD, COAD, CHOL and THCA and higher tumor expression in PRAD. The LUSC box plot shows higher STRADBP1 RNA expression in normal versus tumor tissue (log2 FC = −0.241, t-test p < 0.001).
This table shows molecular features associated with STRADBP1 in patient tissues and cancer cell lines. In patient samples, STRADBP1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
